---
title: "Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296264806.md"
description: "Stoke Therapeutics (Nasdaq: STOK) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On August 17, 2026, the company granted stock options for 70,950 shares to seven new employees. The exercise price is $32.13 per share, matching the closing price on that date. Options vest over four years and have a 10-year term, subject to the 2023 Inducement Plan."
datetime: "2026-08-18T12:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296264806.md)
  - [en](https://longbridge.com/en/news/296264806.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296264806.md)
generator: "portal-rs"
---

# Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of $32.13 per share, which is equal to the closing price of Stoke’s common stock on August 17, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

**About Stoke Therapeutics**

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260818431748/en/

**Stoke Media & Investor Contacts:**  
Susan Willson  
Vice President, Corporate Communications  
swillson@stoketherapeutics.com  
415-509-8202

Investor Relations  
IR@stoketherapeutics.com  
508-642-6485

Source: Stoke Therapeutics, Inc.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [FY2029 Earnings Estimate for STOK Issued By HC Wainwright](https://longbridge.com/en/news/294953651.md)
- [Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RNA Stock News](https://longbridge.com/en/news/296542298.md)
- [18:23 ETAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/296541925.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**